10 Amazing Drugs That You’ll Hear Much About in the Next Decade

The world of medicine is constantly advancing, bringing new hope with each breakthrough. Over the next decade, a handful of medications are expected to stand out for their impact. These drugs are not just about scientific progress—they’re about changing lives and offering new solutions where there were none before.

Whether tackling chronic illnesses or introducing treatments for conditions once deemed untreatable, these medications are paving the way for a healthier future. They promise not just improved health outcomes but also a better quality of life for countless people around the globe.

In this list, we’ll explore ten amazing drugs that are set to become game-changers in their respective fields. These are the names you’ll hear more often as they continue to revolutionize healthcare.

Related: 10 Medicines That Work But We Don’t Know Why

10 Harvoni: Revolutionizing Hepatitis C Treatment

Imagine a world where hepatitis C is no longer a chronic, debilitating disease. Enter Harvoni, a breakthrough medication that combines ledipasvir and sofosbuvir. This dynamic duo works by blocking proteins the hepatitis C virus needs to grow. The result? An impressive cure rate of 94% to 99%, turning what was once a life-long battle into a manageable, short-term treatment.

For many patients, Harvoni means taking just one pill a day for two to six months. This simplicity is a game-changer, especially for those dealing with genotype 1, the most common strain in the U.S. Harvoni’s approval for use in children, adults, and even those with complicated cases involving HIV or liver transplants makes it a versatile tool in the fight against hepatitis C.

However, this groundbreaking treatment doesn’t come cheap, with a hefty price tag of around $1,100 per pill. Yet, for many, the chance to live free from hepatitis C is priceless, making Harvoni a true revolution in antiviral therapy.^[1]

9 Aimovig: A Breakthrough for Migraine Relief

For those battling migraines, the search for relief often feels endless. Aimovig offers a new approach. This FDA-approved drug belongs to a class known as CGRP monoclonal antibodies, which target calcitonin gene-related peptide, a protein linked to migraine pain. By blocking CGRP, Aimovig aims to prevent migraines before they start.

What makes Aimovig unique is its focus on migraine prevention, unlike older treatments originally designed for other conditions. Patients have reported significant reductions in migraine frequency, with some experiencing up to eight fewer migraine days per month.

This means a notable improvement in daily life for many chronic migraine sufferers. With its targeted mechanism, Aimovig stands out in the evolving field of migraine treatment, offering hope and a better quality of life to millions affected by this condition.^[2]

8 Evrysdi (Risdiplam): Transforming Spinal Muscular Atrophy Care

Evrysdi, or risdiplam, offers new hope for those with spinal muscular atrophy (SMA). Developed by Genentech, this oral medication boosts the production of the SMN protein, which is essential for motor neuron survival. Unlike earlier treatments that require injections, Evrysdi can be taken at home, making it more convenient for patients of all ages.

Clinical trials, such as FIREFISH and SUNFISH, have shown promising results. In the FIREFISH study, 90% of infants treated with Evrysdi survived without permanent ventilation after 12 months. The SUNFISH trial also reported significant motor function improvements in older patients, showcasing Evrysdi’s effectiveness across different age groups.

With FDA approval, Evrysdi represents a significant step forward in genetic medicine. It highlights the move towards more accessible and effective treatments for rare genetic disorders, offering a better quality of life for SMA patients.^[3]

7 Hemgenix: A Breakthrough in Hemophilia B Treatment

Hemgenix, developed by CSL Behring, is revolutionizing Hemophilia B treatment. Approved by the FDA in 2022, this gene therapy delivers a functional copy of the F9 gene to liver cells, allowing patients to produce clotting factor IX. In clinical trials, Hemgenix increased factor IX levels and reduced bleeding episodes by 64%.

Patients treated with Hemgenix, like those in France, have reported fewer bleeding incidents and improved quality of life. This one-time infusion reduces the need for regular treatments, offering a significant shift in managing Hemophilia B.

Ongoing research aims to confirm Hemgenix’s long-term benefits and safety. This therapy holds promise for transforming care for Hemophilia B patients, potentially reducing complications and enhancing independence.^[4]

6 Dupixent (Dupilumab): A Potential Future Treatment for Keloids

Dupixent, a monoclonal antibody known as dupilumab, has demonstrated potential in preventing keloid formation and alleviating related symptoms. Keloid scars, resulting from abnormal healing processes, are often challenging to treat effectively. Traditional treatments like corticosteroid injections frequently offer limited relief. Recent case studies have shown that dupilumab can reduce inflammation and prevent new keloids in patients with recurrent skin injuries, suggesting its promise as a novel treatment approach.

In one notable case, a 23-year-old woman with chronic keloids on her shoulders and chest experienced significant improvements after starting dupilumab. Previous treatments had failed, but with dupilumab, her keloids stabilized, and symptoms like pain and itching diminished. Similarly, a 20-year-old woman with multiple keloids from acne reported fewer new keloids and reduced discomfort after initiating dupilumab therapy. These cases highlight dupilumab’s potential in keloid prevention and management.

Ongoing clinical trials are exploring dupilumab’s efficacy in treating keloids. While these initial findings are promising, more research is needed to establish dupilumab as a definitive treatment for keloids, offering hope for patients seeking relief from this challenging condition.^[5]

5 Trikafta: A New Dawn for Cystic Fibrosis

The introduction of Trikafta in 2019 marked a significant breakthrough for individuals with cystic fibrosis (CF), transforming lives previously constrained by the disease. Trikafta, a triple combination drug, targets the defective cystic fibrosis transmembrane conductance regulator (CFTR) protein, improving lung function by thinning and clearing mucus.

Patients often experience increased mucus clearance, making breathing easier and enhancing daily life activities. Although long-term studies are ongoing, initial results suggest that Trikafta can potentially extend life expectancy and significantly improve the quality of life for many CF patients.

Jenny Livingston’s story exemplifies Trikafta’s impact. Diagnosed with CF at birth, she endured frequent hospitalizations and declining health. However, after starting Trikafta, her condition stabilized, allowing her to participate in activities she once couldn’t. Now, Jenny plans for a future with her daughter, something previously unimaginable.

While Trikafta is not a cure and may not be effective for all CF patients, its ability to transform many patients’ lives is undeniable. It’s important to note that some patients may experience side effects. Ongoing research continues to explore Trikafta’s full potential, promising even greater improvements in CF treatment.^[6]

4 Lecanemab: A New Frontier in Alzheimer’s Treatment

Lecanemab, developed by Biogen and Eisai, represents a promising advance in Alzheimer’s disease treatment. This monoclonal antibody targets amyloid plaques in the brain, which are associated with cognitive decline. Initially granted accelerated approval in January 2023 based on its ability to reduce amyloid plaques, lecanemab received full FDA approval in July 2023 after further clinical data confirmed its clinical benefit. In trials, lecanemab has shown modest but significant effects in slowing the progression of cognitive decline, providing a new option for patients and their families.

By administering intravenously every two weeks, lecanemab offers a consistent approach to managing Alzheimer’s. Although not a cure, it helps delay the disease’s progression, allowing patients to maintain their independence longer. The Alzheimer’s community views lecanemab as a crucial step forward, with ongoing research aiming to further validate and expand its benefits.

Dr. Lawrence Honig, a neurologist at NewYork-Presbyterian, emphasizes that lecanemab is one of the first treatments to show measurable effects in slowing Alzheimer’s progression. As research continues, lecanemab could become a cornerstone in Alzheimer’s care, providing much-needed hope and improved outcomes for patients and their families.^[7]

3 Scemblix: A Game-Changer in Chronic Myeloid Leukemia Treatment

Scemblix, developed by Novartis, has emerged as a significant advancement in the treatment of chronic myeloid leukemia (CML). Approved by the FDA in 2021, this novel drug targets the BCR-ABL1 protein, a key driver of CML. Recent data from the Phase III ASC4FIRST study, presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) Congress, demonstrated Scemblix’s superior efficacy compared to other tyrosine kinase inhibitors (TKIs) in newly diagnosed CML patients.

Patients treated with Scemblix showed higher rates of major molecular response and lower discontinuation rates due to adverse effects compared to those on traditional TKIs. This makes Scemblix not only a more effective option but also a more tolerable one for many patients. With its ability to provide better outcomes and improved tolerability, Scemblix is setting a new standard in leukemia care, offering hope and a higher quality of life for those affected by CML.^[8]

2 Zolgensma: A Gene Therapy Medical Miracle for Spinal Muscular Atrophy

Zolgensma, a groundbreaking gene therapy developed by Novartis, has revolutionized the treatment of spinal muscular atrophy (SMA), a severe genetic disorder that affects muscle strength and movement. Approved by the FDA in 2019, Zolgensma works by delivering a functional copy of the SMN1 gene to replace the missing or defective gene in SMA patients. This one-time intravenous infusion is designed for children under the age of two and has shown remarkable efficacy in clinical trials, significantly improving motor functions and extending life expectancy.

The impact of Zolgensma on patients’ lives is profound. Children who received this therapy have achieved developmental milestones previously thought impossible for SMA patients, such as sitting up, crawling, and even walking. For instance, twins Kali and Kaiden, diagnosed with SMA Type 1, received Zolgensma at one month old and have since shown tremendous progress, defying the grim prognosis typically associated with the disease. Their story, along with others, underscores the transformative potential of gene therapy in treating genetic disorders.

Despite its high cost, Zolgensma offers hope and a better quality of life for families affected by SMA. As ongoing research continues to evaluate its long-term benefits and safety, Zolgensma stands as a testament to the advancements in genetic medicine, providing a new lease on life for many young patients.^[9]

1 Ketruda (Pembrolizumab): Extending Survival in Kidney Cancer Patients

Keytruda (Pembrolizumab) is making waves as an adjuvant therapy for kidney cancer, particularly clear-cell renal cell carcinoma (RCC). Approved by the FDA in 2021, this immunotherapy works by targeting the PD-1 protein, enhancing the immune system’s ability to attack cancer cells. The KEYNOTE-564 trial revealed that patients treated with pembrolizumab post-surgery had a nearly 40% reduced risk of death compared to a placebo. Four years into treatment, 91% of patients on pembrolizumab were still alive, compared to 86% in the placebo group.

These results are groundbreaking, marking the first time an adjuvant therapy for kidney cancer has shown improved overall survival. Despite potential side effects like fatigue and rash, pembrolizumab offers new hope for patients at high risk of recurrence. Oncologists are optimistic about its potential to become a standard post-surgical treatment, significantly improving care and outcomes for early-stage kidney cancer patients. ^[10]